Tested compounds selected by two different in silico modes and respective UGT2B10 metabolism selectivity using HLM(-)
| Selection Mode | Drug | Selective UGT2B10 Substrate |
|---|---|---|
| Ligand-based | Alprenolol | No |
| Asenapine | Yes | |
| Bifonazole | Yes | |
| Carbamazepine | N.D. | |
| Clozapine | No | |
| Cyproheptadine | Yes | |
| Imidafenacin | N.D. | |
| Lamotrigine | No | |
| Lidocaine | N.D. | |
| Loxapine | No | |
| Miconazole | No | |
| Norclozapine | N.D. | |
| Oxymetazoline | No | |
| Propranolol | No | |
| Sertraline | N.D. | |
| Sulconazole | No | |
| Tamoxifen | No | |
| Tioconazole | No | |
| Varenicline | N.D. | |
| Substructure | Azatadine | Yes |
| Cidoxepin | Yes | |
| Cyclobenzaprine | Yes | |
| Dothiepin | Yes | |
| Rupatadine | No |
N.D., below the limit of glucuronide compound detection in the pooled HLM.